Outcomes by line of therapy and programmed death ligand 1 expression in patients with advanced melanoma treated with pembrolizumab or ipilimumab in KEYNOTE-006: A randomised clinical trial
European Journal of Cancer2018Vol. 101, pp. 236–243
Citations Over TimeTop 10% of 2018 papers
Matteo S. Carlino, Georgina V. Long, Dirk Schadendorf, Caroline Robert, Antoni Ribas, Erika Richtig, Marta Nyakas, Christian Caglevic, Ahmed Tarhini, Christian U. Blank, Christoph Höeller, Gil Bar‐Sela, Catherine Barrow, Pascal Wolter, Haiyu Zhou, Kenneth Emancipator, Erin Jensen, Scot Ebbinghaus, Nageatte Ibrahim, Adil Daud
Abstract
NCT01866319.
Related Papers
- → Patient-reported outcomes in KEYNOTE-006, a randomised study of pembrolizumab versus ipilimumab in patients with advanced melanoma(2017)88 cited
- → Antitumor activity of ipilimumab or BRAF ± MEK inhibition after pembrolizumab treatment in patients with advanced melanoma: analysis from KEYNOTE-006(2021)15 cited
- → Pembrolizumab in a BRAF -Mutant Metastatic Melanoma Patient Following a Severe Immune-Related Adverse Event with Ipilimumab(2016)8 cited
- → A plain language summary from pembrolizumab plus ipilimumab following PD-1 antibody failure in melanoma(2022)
- → Data from Prolonged Benefit from Ipilimumab Correlates with Improved Outcomes from Subsequent Pembrolizumab(2023)